BR112012000287A2 - composição farmacêutica para um inibidor de protease viral de hepatite c - Google Patents
composição farmacêutica para um inibidor de protease viral de hepatite cInfo
- Publication number
- BR112012000287A2 BR112012000287A2 BR112012000287A BR112012000287A BR112012000287A2 BR 112012000287 A2 BR112012000287 A2 BR 112012000287A2 BR 112012000287 A BR112012000287 A BR 112012000287A BR 112012000287 A BR112012000287 A BR 112012000287A BR 112012000287 A2 BR112012000287 A2 BR 112012000287A2
- Authority
- BR
- Brazil
- Prior art keywords
- hepatitis
- pharmaceutical composition
- protease inhibitor
- viral protease
- viral
- Prior art date
Links
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22350709P | 2009-07-07 | 2009-07-07 | |
| US61/223,507 | 2009-07-07 | ||
| PCT/US2010/040734 WO2011005646A2 (en) | 2009-07-07 | 2010-07-01 | Pharmaceutical composition for a hepatitis c viral protease inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012000287A2 true BR112012000287A2 (pt) | 2016-02-23 |
| BR112012000287B1 BR112012000287B1 (pt) | 2020-12-08 |
| BR112012000287B8 BR112012000287B8 (pt) | 2021-05-25 |
Family
ID=43245003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012000287A BR112012000287B8 (pt) | 2009-07-07 | 2010-07-01 | composição farmacêutica para um inibidor de protease viral de hepatite c |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9034831B2 (pt) |
| EP (1) | EP2451438B8 (pt) |
| JP (1) | JP5607736B2 (pt) |
| KR (1) | KR101685941B1 (pt) |
| CN (1) | CN102470103B (pt) |
| AP (1) | AP2011005979A0 (pt) |
| AR (1) | AR077393A1 (pt) |
| AU (1) | AU2010270783B2 (pt) |
| BR (1) | BR112012000287B8 (pt) |
| CA (1) | CA2767692C (pt) |
| CL (1) | CL2012000054A1 (pt) |
| CO (1) | CO6480980A2 (pt) |
| DK (1) | DK2451438T3 (pt) |
| EA (1) | EA023433B1 (pt) |
| EC (1) | ECSP12011624A (pt) |
| ES (1) | ES2464367T3 (pt) |
| GE (1) | GEP20146016B (pt) |
| HR (1) | HRP20140445T1 (pt) |
| IL (1) | IL216098A (pt) |
| MA (1) | MA33491B1 (pt) |
| ME (1) | ME01718B (pt) |
| MX (1) | MX2011013824A (pt) |
| MY (1) | MY154683A (pt) |
| NZ (1) | NZ596928A (pt) |
| PE (1) | PE20120322A1 (pt) |
| PL (1) | PL2451438T3 (pt) |
| PT (1) | PT2451438E (pt) |
| RS (1) | RS53209B (pt) |
| SG (1) | SG177569A1 (pt) |
| SI (1) | SI2451438T1 (pt) |
| TN (1) | TN2012000009A1 (pt) |
| TW (1) | TWI490216B (pt) |
| UA (1) | UA104195C2 (pt) |
| UY (1) | UY32760A (pt) |
| WO (1) | WO2011005646A2 (pt) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2337583A1 (en) * | 2008-09-17 | 2011-06-29 | Boehringer Ingelheim International GmbH | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
| WO2011005646A2 (en) | 2009-07-07 | 2011-01-13 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition for a hepatitis c viral protease inhibitor |
| BR112012010110A2 (pt) | 2009-10-30 | 2019-09-24 | Boehringer Ingelheim Int | regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina |
| AP2013006734A0 (en) | 2010-09-30 | 2013-02-28 | Boehringer Ingelheim Int | Combination therapy for treating HCV infection |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2811203C (en) | 2011-10-21 | 2015-05-05 | Abbvie Inc. | Methods for treating hcv |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| MX2014008205A (es) | 2012-01-12 | 2014-08-08 | Boehringer Ingelheim Int | Formulaciones farmaceuticas estabilizadas de un potente inhibidor de hcv. |
| JP2015509980A (ja) | 2012-03-14 | 2015-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法 |
| WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
| WO2013143581A1 (en) | 2012-03-28 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in specific patient subgenotype sub-population |
| SI2909205T1 (sl) | 2012-10-19 | 2017-02-28 | Bristol-Myers Squibb Company | 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| CN105228593B (zh) * | 2013-03-15 | 2018-08-28 | 勃林格殷格翰国际有限公司 | 呈无定形状态的hcv抑制剂的固体口服剂型 |
| EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
| JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
| CN114651010A (zh) | 2019-04-24 | 2022-06-21 | 赛诺菲生物技术公司 | 类风湿性关节炎的诊断和治疗方法 |
| KR20230061198A (ko) | 2019-06-04 | 2023-05-08 | 사노피 바이오테크놀로지 | 류마티스성 관절염을 갖는 대상체에서 통증을 치료하기 위한 조성물 및 방법 |
| AU2021253796B2 (en) | 2020-04-05 | 2023-06-01 | Pfizer Inc. | Compounds and methods for the treatment of COVID-19 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE445174B (sv) | 1978-03-07 | 1986-06-09 | Sandoz Ag | Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans |
| US5342625A (en) | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| IL102236A0 (en) | 1991-06-27 | 1993-01-14 | Ltt Inst Co Ltd | Topical preparations containing cyclosporin |
| US5329976A (en) | 1991-12-09 | 1994-07-19 | Habley Medical Technology Corporation | Syringe-filling and medication mixing dispenser |
| GB9208712D0 (en) | 1992-04-22 | 1992-06-10 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporin derivates |
| ES2308955T5 (es) | 1993-09-28 | 2012-04-03 | R.P. Scherer Gmbh | Fabricación de cápsulas de gelatina blanda |
| EP0825849A1 (en) | 1995-05-19 | 1998-03-04 | Abbott Laboratories | Self-emulsifying formulations of lipophilic drugs |
| US5993858A (en) | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
| NZ502566A (en) * | 1997-07-29 | 2002-03-28 | Upjohn Co | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation containing a pyranone and a basic amine |
| CA2294032A1 (en) | 1997-07-29 | 1999-02-11 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
| CN1208047C (zh) * | 1997-07-29 | 2005-06-29 | 法玛西雅厄普约翰美国公司 | 亲脂性化合物的自体乳化剂 |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6652880B1 (en) | 1999-04-01 | 2003-11-25 | R.P. Scherer Technologies, Inc. | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
| SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| GB0008785D0 (en) | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| US6710195B2 (en) | 2001-11-26 | 2004-03-23 | Supergen, Inc. | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
| US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| CZ294371B6 (cs) | 2002-06-10 | 2004-12-15 | Pliva - Lachema, A. S. | Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy |
| US20040033959A1 (en) | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| UY28240A1 (es) | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
| UA81028C2 (en) | 2003-04-02 | 2007-11-26 | Boehringer Ingelheim Int | Pharmaceutical compositions for hepatitis c viral protease inhibitors |
| HRP20080014T3 (en) * | 2003-05-21 | 2008-02-29 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| RS20060197A (sr) | 2003-09-22 | 2008-09-29 | Boehringer Ingelheim International Gmbh., | Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa |
| JP4654239B2 (ja) | 2004-03-15 | 2011-03-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎ウィルス感染症の治療に適した大環状ジペプチドの調製方法 |
| AU2005228894B9 (en) | 2004-03-30 | 2011-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| WO2005116054A1 (en) | 2004-05-25 | 2005-12-08 | Boehringer Ingelheim International, Gmbh | Process for preparing acyclic hcv protease inhibitors |
| US20060276406A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
| KR20100118991A (ko) | 2008-02-04 | 2010-11-08 | 아이데닉스 파마슈티칼스, 인코포레이티드 | 매크로시클릭 세린 프로테아제 억제제 |
| AU2009293494B2 (en) | 2008-09-16 | 2014-04-24 | Boehringer Ingelheim International Gmbh | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor |
| RS53121B (sr) | 2008-11-21 | 2014-06-30 | Boehringer Ingelheim International Gmbh | Farmaceutska kompozicija snažnog hcv inhibitora za oralnu primenu |
| WO2011005646A2 (en) | 2009-07-07 | 2011-01-13 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition for a hepatitis c viral protease inhibitor |
-
2010
- 2010-07-01 WO PCT/US2010/040734 patent/WO2011005646A2/en not_active Ceased
- 2010-07-01 KR KR1020127000354A patent/KR101685941B1/ko not_active Expired - Fee Related
- 2010-07-01 UA UAA201201066A patent/UA104195C2/ru unknown
- 2010-07-01 ES ES10731685.3T patent/ES2464367T3/es active Active
- 2010-07-01 PT PT107316853T patent/PT2451438E/pt unknown
- 2010-07-01 GE GEAP201012562A patent/GEP20146016B/en unknown
- 2010-07-01 EA EA201200096A patent/EA023433B1/ru not_active IP Right Cessation
- 2010-07-01 MY MYPI2012000028A patent/MY154683A/en unknown
- 2010-07-01 AP AP2011005979A patent/AP2011005979A0/xx unknown
- 2010-07-01 NZ NZ596928A patent/NZ596928A/xx not_active IP Right Cessation
- 2010-07-01 ME MEP-2014-23A patent/ME01718B/me unknown
- 2010-07-01 CN CN201080030433.1A patent/CN102470103B/zh not_active Expired - Fee Related
- 2010-07-01 JP JP2012519597A patent/JP5607736B2/ja not_active Expired - Fee Related
- 2010-07-01 AU AU2010270783A patent/AU2010270783B2/en not_active Ceased
- 2010-07-01 CA CA2767692A patent/CA2767692C/en not_active Expired - Fee Related
- 2010-07-01 SG SG2012001368A patent/SG177569A1/en unknown
- 2010-07-01 MA MA34511A patent/MA33491B1/fr unknown
- 2010-07-01 PE PE2011002086A patent/PE20120322A1/es active IP Right Grant
- 2010-07-01 DK DK10731685.3T patent/DK2451438T3/da active
- 2010-07-01 HR HRP20140445AT patent/HRP20140445T1/hr unknown
- 2010-07-01 BR BR112012000287A patent/BR112012000287B8/pt not_active IP Right Cessation
- 2010-07-01 MX MX2011013824A patent/MX2011013824A/es active IP Right Grant
- 2010-07-01 SI SI201030565T patent/SI2451438T1/sl unknown
- 2010-07-01 EP EP10731685.3A patent/EP2451438B8/en active Active
- 2010-07-01 RS RS20140116A patent/RS53209B/sr unknown
- 2010-07-01 PL PL10731685T patent/PL2451438T3/pl unknown
- 2010-07-05 UY UY0001032760A patent/UY32760A/es not_active Application Discontinuation
- 2010-07-06 US US12/830,771 patent/US9034831B2/en active Active
- 2010-07-06 TW TW099122196A patent/TWI490216B/zh not_active IP Right Cessation
- 2010-07-06 AR ARP100102427A patent/AR077393A1/es not_active Application Discontinuation
-
2011
- 2011-11-02 IL IL216098A patent/IL216098A/en active IP Right Grant
- 2011-12-29 CO CO11181070A patent/CO6480980A2/es not_active Application Discontinuation
-
2012
- 2012-01-05 TN TNP2012000009A patent/TN2012000009A1/en unknown
- 2012-01-06 CL CL2012000054A patent/CL2012000054A1/es unknown
- 2012-01-26 EC EC2012011624A patent/ECSP12011624A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL216098A0 (en) | Pharmaceutical composition for a hepatitis c viral protease inhibitor | |
| LTC2410844I2 (lt) | Hepatito C viruso replikacijos inhibitoriai | |
| CY2015012I2 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
| LT3061445T (lt) | Labai koncentruotos farmacinės kompozicijos | |
| BRPI1007836A2 (pt) | Inibidores do vírus c da hepatite | |
| BRPI1008846A2 (pt) | inibidores do vírus da hepatite c | |
| BRPI1013393A2 (pt) | inibidores do vírus da hepatite c | |
| BRPI1014084A2 (pt) | inibidores do vírus da hepatite c | |
| DK2242752T3 (da) | Imidazolyl-biphenylimidazoler som hepatitis C-virus-inhibitorer | |
| DK2242515T3 (da) | Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering | |
| IL219516A0 (en) | Hepatitis c virus inhibitors | |
| IL219517A0 (en) | Hepatitis c virus inhibitors | |
| EP2475256A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| IL215095A0 (en) | Hepatitis c virus inhibitors | |
| EP2512480A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| BRPI1004940A2 (pt) | composição farmacêutica | |
| BRPI1015939A2 (pt) | composição farmacêutica | |
| BR112012003149A2 (pt) | composição farmacêutica | |
| BRPI1006924A2 (pt) | composições farmacêuticas compreendendo um profármaco inibidor de polimerase de hcv | |
| CO7000774A2 (es) | Formulaciones farmacéuticas estabilizadas de un potente inhibidor de hcv | |
| FR2951945B1 (fr) | Composition pharmaceutique | |
| TH105924B (th) | สารยับยั้งไวรัสตับอักเสบ c | |
| DOP2009000016A (es) | Composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/07/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 12A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2677 DE 26-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |